Differentiation therapy in acute myeloid leukaemia: molecular basis, clinical progress, and future perspectives - Top-Institutions - MDSpire

Differentiation therapy in acute myeloid leukaemia: molecular basis, clinical progress, and future perspectives

  • By

  • Abdulaziz Asiri

  • May 18, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Hematology
    • Oncology

  • #2

    Cancer Genome Atlas Research Network
    Cancer Genome Atlas Research Network

    N/A, N/A

    Key Differentiators

    • Genomics
    • Hematology

  • #3

    Moffitt Cancer Center
    Moffitt Cancer Center

    Tampa, Florida

    Key Differentiators

    • Hematology
    • Oncology

  • #4

    Eastern Cooperative Oncology Group (ECOG)
    Eastern Cooperative Oncology Group (ECOG)

    N/A, N/A

    Key Differentiators

    • Oncology
    • Clinical Trials

  • #5

    Policlinico Tor Vergata
    Policlinico Tor Vergata

    Rome, Italy

    Key Differentiators

    • Hematology

Original Source(s)

Differentiation therapy in acute myeloid leukaemia: molecular basis, clinical progress, and future perspectives

  • by Abdulaziz Asiri

  • May 18, 2026

Related Content

FOXA2 in cancer: from fundamental biology to clinical translation

The role of NAD+ metabolic reprogramming in colorectal cancer chemoresistance: mechanistic insights, clinical translation challenges and opportunities

Financial Hardship and Nonadherence to Lifestyle and Surveillance in Childhood Cancer Survivors